Detalhe da pesquisa
1.
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
Oncologist
; 28(5): 460-e298, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37010988
2.
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Am J Hematol
; 92(5): 467-472, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28230270
3.
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Br J Haematol
; 169(2): 219-27, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683772
4.
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
J Clin Oncol
; 41(25): 4154-4163, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467452
5.
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
Br J Haematol
; 174(2): 323-5, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26403323
6.
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
Leuk Lymphoma
; 59(9): 2128-2134, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29320913